Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2019 | HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019
NCRI 2019
Breast Cancer Gastrointestinal Cancer Antibodies Trastuzumab

Russell Petty, BMSC, MB ChB, PhD, MRCP, University of Dundee, Dundee, UK, talks about precision cancer biology and the phenomenon of HER-2 conversion that occurs in trastuzumab resistance. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Russell Petty

3:09
Precision medicine in gastrointestinal cancers: promise and pitfalls
Russell Petty • 5 Nov 2019

Related Videos

2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
0:56
Adjuvant chemotherapy in biliary tract cancer post-tumor resection
Olatunji Alese • 8 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals